Eversana (PRIVATE.EVERSANA)

Overall impact
C (46)

Commentary

Eversana is an average overall performer. With a 'C' rating of 46.4 for overall impact (34th percentile compared to all companies), Eversana ranks 87th out of 96 industry peers, behind Suvoda, Gainwell Technologies, Maximus and 83 others, and ahead of Premier, Inc., Inovalon, Atlantic Vision Partners and 6 others. On top material causes for Eversana's industry (Healthcare Software & Services), Eversana performs well in Technology Innovation (94.7 score) and performs poorly in Reduced Green House Gas Emissions (34.9 score), Sustainable Use of Natural Resources (24.3), Racial Justice and Civil Rights (38.5) and 6 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.EVERSANA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2009
Employees
6,000
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Illinois, United States
Share classes
PRIVATE.EVERSANA
Description
Operator of an integrated and independent commercial services platform designed to solve pricing, access, reimbursement, adherence and product delivery challenges in the life science sector. The company offers clinical trial recruitment and comprehensive patient support along with drug safety, consulting and management services to pharmaceutical enterprises. This helps them provide critical therapies to market easily.
Material causes
Ethos considers the following causes material for Eversana, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.